

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF GLAND PHARMA LIMITED

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2026 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the quarter and year ended March 31, 2026" of **GLAND PHARMA LIMITED** (the "Company"), (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2026:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2026

With respect to the Standalone Financial Results for the quarter ended March 31, 2026, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2026

We conducted our audit in accordance with the Standards on Auditing ("SA's) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2026 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2026

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2026

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under Section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

The Statement includes the results for the Quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)



Monisha Parikh
Partner

Membership No. 047840
UDIN: 26047840ED9XGM4973

Place: Seoul
Date: May 15, 2026

**GLAND PHARMA LIMITED**

Corporate Identity Number: L24239TG1978PLC002276

Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandhi Maisamma 'X' Roads, D.P. Pally, Dundigal

Dundigal - Gandhi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India

Tel: +91 84556 99999; Website: www.glandpharma.com; E-mail: investors@glandpharma.com

Statement of Standalone Financial Results for the quarter and year ended March 31, 2026

(₹ in million)

Particulars	Quarter ended			Year ended	
	31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
	Unaudited	Unaudited	Unaudited	Audited	Audited
1. Income					
Revenue from operations	12,615.92	11,775.13	10,303.53	45,520.92	41,161.49
Other income	1,063.57	602.07	437.18	3,038.97	2,150.75
Total income	13,679.49	12,377.20	10,740.71	48,559.89	43,312.24
2. Expenses					
Cost of materials consumed	4,609.57	4,348.48	4,693.92	17,952.19	15,858.57
Purchase of stock-in-trade	22.78	15.01	30.99	66.04	144.88
Changes in inventories of finished goods, stock-in-trade and work-in-progress	215.54	279.32	(672.78)	(66.65)	1,302.49
Power and fuel	298.24	295.39	286.27	1,223.83	1,203.82
Employee benefits expense	1,339.56	1,341.42	1,196.95	5,288.18	4,390.23
Depreciation and amortisation expense	431.10	445.30	430.72	1,762.43	1,692.71
Finance costs	61.65	5.02	34.46	180.73	228.37
Other expenses	1,053.06	1,279.24	826.95	4,426.57	3,835.32
Total expenses	8,031.50	8,009.18	6,827.48	30,833.32	28,656.39
3. Profit before exceptional item and tax (1-2)	5,647.99	4,368.02	3,913.23	17,726.57	14,655.85
4. Exceptional item (refer note 3)	-	243.46	-	243.46	-
5. Profit before tax (3-4)	5,647.99	4,124.56	3,913.23	17,483.11	14,655.85
6. Tax expense					
Current tax	1,432.14	1,101.36	990.22	4,525.19	3,654.80
Deferred tax	11.34	(55.97)	22.52	(38.29)	91.24
Taxes of earlier years	-	0.70	0.50	0.70	12.28
Total tax expense	1,443.48	1,046.09	1,013.24	4,487.60	3,758.32
7. Profit for the quarter/year (5-6)	4,204.51	3,078.47	2,899.99	12,995.51	10,897.53
8. Other comprehensive income					
<i>Items that will not be reclassified subsequently to profit or loss:</i>					
Remeasurement of defined benefit plans	(74.69)	(2.71)	61.37	(86.51)	39.09
Deferred tax impact on remeasurement of defined benefit plans	18.79	0.69	(15.45)	21.77	(9.84)
Total other comprehensive (income)/loss, net of tax	(55.90)	(2.02)	45.92	(64.74)	29.25
9. Total comprehensive income (7-8)	4,260.41	3,080.49	2,854.07	13,060.25	10,868.28
10. Paid up equity share capital (Face value of ₹1/- each)	164.76	164.76	164.76	164.76	164.76
11. Other equity				107,935.57	97,386.26
12. Earnings per equity share (Face value of ₹1/- each):					
<i>(Not annualised for the quarter)</i>					
Basic (₹)	25.52	18.68	17.60	78.88	66.15
Diluted (₹)	25.49	18.68	17.60	78.78	66.15



Notes:

1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing requirements"), this Statement of Standalone Financial Results for the quarter and year ended March 31, 2026 ("Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 15, 2026. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31, 2026 and have issued an unmodified conclusion on the financial results for the quarter ended March 31, 2026.
2. The Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of the Listing requirements.
3. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz. The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020, and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These New Labour Codes became effective from 21 November 2025.
Subsequent to the year-end, the Central Government has notified the Code on Wages (Central) Rules, 2026, the Industrial Relations (Central) Rules, 2026, the Code on Social Security (Central) Rules, 2026, and the Occupational Safety, Health and Working Conditions (Central) Rules, 2026. The corresponding State Rules and certain other operational clarifications under the New Labour Codes are yet to be notified.
The Company has assessed the implications of the New Labour Codes and has made an additional provision of ₹ 243.46 million for gratuity and leave liability towards employee benefits during the quarter ended December 31, 2025, and year ended March 31, 2026. Considering the regulatory driven and non - recurring nature of the impact, the Company has presented the incremental impact as an "Exceptional item". The Company will continue to monitor the notification of the remaining State Rules and clarifications, and would provide appropriate accounting effect based on the developments, if any.
4. An expense of ₹114.21 million and ₹454.68 million have been recognised for the quarter and year ended March 31, 2026, respectively, towards employee stock option compensation expenses, in accordance with the 'Gland Pharma Employee Stock Option Scheme 2025' and the requirements of Ind AS 102 – 'Share-based Payment'.
5. The Company is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'.
6. The Audited Standalone Balance Sheet and Audited Standalone Statement of Cash Flows are set out in **Annexure I** and **Annexure II** respectively.
7. The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the end of the third quarter of the relevant financial year, which were subjected to a limited review.
8. The Board of Directors of the Company at its meeting held on May 15, 2026 has recommended a final dividend of ₹ 20 per equity share (face value of ₹ 1 each) for the financial year ended March 31, 2026. The dividend is subject to approval of the shareholders in the ensuing Annual General Meeting of the Company.
9. The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform with the current period presentation.
10. The above Standalone Financial Results of the Company are available on the Company's website www.glandpharma.com and also on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com), where the equity shares of the Company are listed.



Hyderabad
May 15, 2026

For and on behalf of the Board
Gland Pharma Limited

S. Srinivas

Srinivas Sadu
Executive Chairman
DIN No. 06900659

Audited Standalone Balance Sheet as at March 31, 2026

Annexure I

(₹ in million)

Particulars	As at	As at
	31-Mar-26	31-Mar-25
	Audited	Audited
ASSETS		
Non-current assets		
Property, plant and equipment	16,839.42	17,358.57
Right-of-use assets	24.96	26.74
Capital work-in-progress	1,376.28	422.05
Other intangible assets	19.91	64.58
Financial assets		
Investments	32,925.52	27,895.67
Tax assets, net	55.60	274.50
Other non-current assets	608.29	504.44
	51,849.98	46,546.55
Current assets		
Inventories	12,651.97	12,542.33
Financial assets		
Trade receivables	15,206.93	11,428.99
Cash and cash equivalents	31,776.39	24,326.22
Other financial assets	737.05	4,935.31
Other current assets	3,849.82	4,436.79
	64,222.16	57,669.64
Total Assets	116,072.14	104,216.19
EQUITY AND LIABILITIES		
Equity		
Equity share capital	164.76	164.76
Other equity	107,935.57	97,386.26
	108,100.33	97,551.02
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	-	11.09
Lease liabilities	24.97	24.05
Provisions	469.10	228.37
Deferred tax liabilities, net	1,147.49	1,164.01
	1,641.56	1,427.52
Current liabilities		
Financial liabilities		
Borrowings	-	14.42
Lease liabilities	2.49	2.70
Trade payables		
Total outstanding dues of micro and small enterprises	176.42	63.01
Total outstanding dues of creditors other than micro and small enterprises	4,677.30	3,795.65
Other financial liabilities	337.09	204.84
Provisions	73.75	57.23
Current tax liabilities, net	554.50	441.47
Other current liabilities	508.70	658.33
	6,330.25	5,237.65
Total Equity and Liabilities	116,072.14	104,216.19



Audited Standalone Statement of Cash Flows for the year ended March 31, 2026

Annexure II

(₹ in million)

Particulars	Year ended	
	31-Mar-26	31-Mar-25
	Audited	Audited
Cash flows from operating activities		
Profit before tax	17,483.11	14,655.85
Adjustments for:		
Depreciation and amortisation expense	1,762.43	1,692.71
Exceptional item (refer note 3)	243.46	-
Allowance for credit losses	4.22	7.71
Other assets written off	-	18.24
Bad debts written off	1.23	-
Finance costs	180.73	228.37
Employee stock option compensation	454.68	-
Unrealised foreign exchange (gain)/loss, net	(430.18)	5.72
Gain on sale of investments	(33.06)	(12.27)
Loss/(gain) on disposal of property, plant and equipment, net	1.13	(0.82)
Interest income	(1,992.89)	(1,991.17)
Changes in operating assets and liabilities:		
Trade receivables	(3,463.91)	220.84
Inventories	(109.64)	59.74
Loans and other assets	559.62	(1,493.90)
Trade payables and other financial liabilities	943.90	1,075.45
Provisions and other liabilities	(58.54)	(208.04)
Cash generated from operations	15,546.29	14,258.43
Income taxes paid, net	(4,193.96)	(3,521.70)
Net cash generated from operating activities (A)	11,352.33	10,736.73
Cash flows from investing activities		
Purchase of property, plant and equipment	(2,179.33)	(1,351.09)
Proceeds from disposal of property, plant and equipment	1.02	237.26
Purchase of investments	(7,439.63)	(4,979.75)
Proceeds from sale of investments	7,472.69	4,992.02
Deposits with banks and others, net	3,960.00	19,408.44
Interest received	2,259.53	1,513.42
Investment made in subsidiary	(5,029.85)	(4,038.32)
Net cash (used in)/generated from investing activities (B)	(955.57)	15,781.98
Cash flows from financing activities		
Proceeds from the exercise of employee stock option	-	24.88
Repayment of borrowings	(25.51)	(7.10)
Payment towards principal portion of lease liabilities	-	(4.02)
Finance costs paid (including interest on lease liabilities)	(170.81)	(114.32)
Dividend paid	(2,965.51)	(3,294.88)
Net cash used in financing activities (C)	(3,161.83)	(3,395.44)
Net increase in cash and cash equivalents (A+B+C)	7,234.93	23,123.27
Effect of exchange differences on cash and cash equivalents held in foreign currency	215.24	40.90
Cash and cash equivalents at the beginning of the year	24,326.22	1,162.05
Cash and cash equivalents at the end of the year	31,776.39	24,326.22

